Exciting new data from our friend and colleague Ben Lipsky and his team highlights a potential shift in how we approach one of our most stubborn challenges: Staphylococcus aureus (StA) in diabetic foot osteomyelitis (DFO). Current standards of care for DFO are often unsatisfactory. This Phase 2, randomized, double-blind, placebo-controlled trial investigated BX211, a personalized... Continue Reading →